Immunocore (NASDAQ:IMCR) Releases Quarterly Earnings Results

Immunocore (NASDAQ:IMCR - Get Free Report) published its earnings results on Wednesday. The company reported an earnings per share (EPS) of ($0.47) for the quarter, which was below analysts' expectations of ($0.31) by a margin of ($0.16), as reported by Zacks. In terms of financial performance, Immunocore experienced a negative net margin of 15.87%, accompanied by a negative return on equity of 12.84%.

Immunocore Stock Performance

During mid-day trading on Wednesday, Immunocore's stock rose by $1.28, reaching a price of $30.49. The trading volume was recorded at 76,482 shares, in comparison to the average volume of 217,221 shares. Over the past year, Immunocore's stock has reached a low of $27.69 and a high of $72.56. The company's market capitalization stands at $1.53 billion, with a price-to-earnings (P/E) ratio of -31.72 and a beta of 0.77. Additionally, Immunocore's quick ratio is 3.76, its current ratio is 3.78, and its debt-to-equity ratio is 1.03. The stock's 50-day simple moving average is $29.98, while its two-hundred-day simple moving average is $31.97.

Analysts Set New Price Targets

Immunocore has been the focus of various recent analysis reports. On January 27th, HC Wainwright reaffirmed a "buy" rating with a target price of $100.00 per share. Meanwhile, Morgan Stanley updated their rating to "equal weight" and set a price objective of $35.00, which is a decrease from their previous target of $74.00. Mizuho downgraded Immunocore from an "outperform" to a "neutral" rating, reducing their price target from $72.00 to $38.00. Additionally, on January 10th, Needham & Company LLC maintained a "buy" rating and a target price of $71.00 for the stock. Currently, the stock has one sell rating, four hold ratings, and eight buy ratings, leading to a consensus rating of "Moderate Buy" with an average target price of $65.64 according to MarketBeat.com.

About Immunocore

Immunocore Holdings plc is a biotechnology company in its commercial stage, focusing on developing immunotherapies to combat cancer, infectious diseases, and autoimmune conditions. One of its primary offerings is KIMMTRAK, which is aimed at treating patients with unresectable or metastatic uveal melanoma. The company is also engaged in developing additional oncology programs, including tebentafusp, which is currently undergoing Phase 2/3 clinical trials for treating advanced cutaneous melanoma.

Earnings, Stocks, Healthcare